Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities
- PMID: 28851981
- PMCID: PMC5574907
- DOI: 10.1038/s41598-017-09860-4
Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities
Abstract
Type 2 diabetes (T2D) has many cardiovascular complications, including a thrombotic propensity. Many such chronic, inflammatory diseases are accompanied (and may be exacerbated, and possibly even largely caused) by amyloid fibril formation. Recognising that there are few strong genetic associations underpinning T2D, but that amyloidogenesis of amylin is closely involved, we have been seeking to understand what might trigger the disease. Serum levels of bacterial lipopolysaccharide are raised in T2D, and we recently showed that fibrin(ogen) polymerisation during blood clotting can be affected strongly by LPS. The selectivity was indicated by the regularisation of clotting by lipopolysaccharide-binding protein (LBP). Since coagulopathies are a hallmark of T2D, we wondered whether they might too be caused by LPS (and reversed by LBP). We show here, using SEM and confocal microscopy, that platelet-poor-plasma from subjects with T2D had a much greater propensity for hypercoagulability and for amyloidogenesis, and that these could both be reversed by LBP. These data imply that coagulopathies are an important feature of T2D, and may be driven by 'hidden' LPS. Given the prevalence of amyloid formation in the sequelae of diabetes, this opens up novel strategies for both the prevention and treatment of T2D.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures










Similar articles
-
Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains.Cardiovasc Diabetol. 2017 Nov 2;16(1):141. doi: 10.1186/s12933-017-0624-5. Cardiovasc Diabetol. 2017. PMID: 29096623 Free PMC article.
-
Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018. PLoS One. 2018. PMID: 29494603 Free PMC article.
-
Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson's Disease, Alzheimer's Disease and Type 2 Diabetes Mellitus.Sci Rep. 2018 Nov 14;8(1):16798. doi: 10.1038/s41598-018-35009-y. Sci Rep. 2018. PMID: 30429533 Free PMC article.
-
Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting.Prog Biophys Mol Biol. 2017 Jan;123:16-41. doi: 10.1016/j.pbiomolbio.2016.08.006. Epub 2016 Aug 21. Prog Biophys Mol Biol. 2017. PMID: 27554450 Review.
-
Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule.Biochem Soc Trans. 2011 Aug;39(4):989-93. doi: 10.1042/BST0390989. Biochem Soc Trans. 2011. PMID: 21787335 Review.
Cited by
-
Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation.Sci Rep. 2019 Feb 28;9(1):3102. doi: 10.1038/s41598-019-39056-x. Sci Rep. 2019. PMID: 30816210 Free PMC article.
-
Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains.Cardiovasc Diabetol. 2017 Nov 2;16(1):141. doi: 10.1186/s12933-017-0624-5. Cardiovasc Diabetol. 2017. PMID: 29096623 Free PMC article.
-
Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies.J Intern Med. 2022 Sep;292(3):523-535. doi: 10.1111/joim.13502. Epub 2022 Apr 27. J Intern Med. 2022. PMID: 35426199 Free PMC article.
-
Platelet activity and hypercoagulation in type 2 diabetes.Cardiovasc Diabetol. 2018 Nov 2;17(1):141. doi: 10.1186/s12933-018-0783-z. Cardiovasc Diabetol. 2018. PMID: 30388964 Free PMC article.
-
Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.Cardiovasc Diabetol. 2019 Jun 4;18(1):72. doi: 10.1186/s12933-019-0870-9. Cardiovasc Diabetol. 2019. PMID: 31164120 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous